Today marks International Thalassaemia Day, a global initiative to raise awareness about this rare genetic blood disorder. Thalassaemia is characterized by reduced haemoglobin levels, which can cause life-threatening anaemia and often requires frequent, lifelong blood transfusions.
- Two main types exist: α-thalassaemia and β-thalassaemia.
- Despite current treatments, many unmet needs remain in managing the disease.
- Cell and gene therapies are emerging as promising approaches, with several already in development or approved globally.
The 2025 theme, “Together for Thalassaemia: Uniting Communities, Prioritising Patients,” highlights the importance of patient-centered care and collaboration across the healthcare ecosystem.
At Asphalion, we are proud to support this mission by working with partners on the development of advanced therapies that aim to significantly improve the lives of those affected by thalassaemia.
Contact us for further information: [email protected]
